Loading...
Arcturus Therapeutics Holdings Community
NasdaqGM:ARCT Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 64 Fair Values set on narratives written by author
Community Investing Ideas
Self-amplifying mRNA Will Meet Aging Global Therapy Demand
Key Takeaways Unique mRNA platform enables rapid market expansion and premium positioning in vaccines, with strong potential for high-margin, recurring revenues and first-mover advantages. Operational efficiency and breakthrough pipeline support sustainable growth, while industry trends drive significant partnering and shareholder value-creation opportunities.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$128.81
93.7% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
89.59% p.a.
Profit Margin
50.12%
Future PE
10.15x
Share price in 2028
US$154.76
Revenues Will Fall And Pipeline Risks Will Hinder RNA Upside
Key Takeaways Heavy reliance on a few clinical programs and uncertain commercialization timelines create considerable risk for sustained revenue and earnings growth. Elevated cash burn, history of losses, and potential delays in partnerships heighten the risk of future dilution or unprofitable expansion.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$42
80.6% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
-47.17% p.a.
Profit Margin
16.25%
Future PE
471.67x
Share price in 2028
US$50.46